CD274 and neoplasm: In particular, checkpoint blockade therapies, such as PD-1/PD-L1 blockade therapies, have been indicated to correct the glucose usage imbalance between tumor cells and T cells by altering glycolysis and directing the energy metabolism to favor T cells (Gubin et al., 2014; Chang et al., 2015; Baumeister et al., 2016; Bengsch et al., 2016; Scharping et al., 2016).